CD86 and prostate cancer: In 1993, Badalament et al [633] from The Ohio State University reported their RIGS feasibility study from ten patients with prostate cancer who were planned for radical retropubic prostatectomy and bilateral pelvic lymphadenectomy and that were intravenously injected with 2 mCi (74 MBq) of 125I-B72.3 monoclonal antibody at an interval from 17 to 38 days prior to the anticipated date of surgery.